MICA and neoplasm: Additionally, dual-targeting CAR-NK cells against PD-L1 and MICA/B in lung cancer showed superior cytotoxicity by addressing tumor heterogeneity [91], while in nasopharyngeal carcinoma, combining CAR-NK cells with nivolumab enhanced NK and CD8+ T cell activity, resulting in synergistic tumor suppression [92].